April 15th 2025
In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection (STI).
Efavirenz Raises Risk of Suicidality
August 3rd 2018New research shows that incidences of suicidality were higher among patients who were prescribed EFV compared to a control group; the results indicate that EFV, rather that treatment initiation timelines, were correlated with suicidal behavior.
Read More
Five Action Steps to Integrate Treatment of Opioid Use Disorder & Infectious Disease Epidemics
July 17th 2018National Academies of Sciences, Engineering, and Medicine workshop highlights 5 key calls for action geared at health providers responsible for treating the infectious complications of patients with opioid use disorder.
Read More